XJPX4527
Market cap4.16bUSD
Dec 24, Last price
2,866.00JPY
1D
2.93%
1Q
-18.30%
Jan 2017
211.86%
Name
Rohto Pharmaceutical Co Ltd
Chart & Performance
Profile
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | ||||||||||
Revenues | 270,840,000 13.48% | 238,664,000 19.54% | 199,646,000 10.27% | |||||||
Cost of revenue | 226,656,000 | 158,775,000 | 130,011,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 44,184,000 | 79,889,000 | 69,635,000 | |||||||
NOPBT Margin | 16.31% | 33.47% | 34.88% | |||||||
Operating Taxes | 10,123,000 | 7,860,000 | 6,803,000 | |||||||
Tax Rate | 22.91% | 9.84% | 9.77% | |||||||
NOPAT | 34,061,000 | 72,029,000 | 62,832,000 | |||||||
Net income | 30,936,000 17.28% | 26,377,000 24.85% | 21,127,000 26.18% | |||||||
Dividends | (5,475,000) | (4,676,000) | (3,422,000) | |||||||
Dividend yield | 0.81% | 0.74% | 0.81% | |||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 1,052,000 | 4,177,000 | 8,033,000 | |||||||
Long-term debt | 6,688,000 | 8,700,000 | 14,534,000 | |||||||
Deferred revenue | 3,146,000 | 3,387,000 | ||||||||
Other long-term liabilities | 5,268,000 | 2,604,000 | 1,124,000 | |||||||
Net debt | (125,201,000) | (99,703,000) | (77,695,000) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 34,245,000 | 30,924,000 | 27,250,000 | |||||||
CAPEX | (7,979,000) | (9,908,000) | (11,328,000) | |||||||
Cash from investing activities | (16,317,000) | (13,176,000) | (16,406,000) | |||||||
Cash from financing activities | (13,784,000) | (16,199,000) | 3,470,000 | |||||||
FCF | 38,079,000 | 59,838,000 | 45,957,000 | |||||||
Balance | ||||||||||
Cash | 89,210,000 | 79,951,000 | 72,791,000 | |||||||
Long term investments | 43,731,000 | 32,629,000 | 27,471,000 | |||||||
Excess cash | 119,399,000 | 100,646,800 | 90,279,700 | |||||||
Stockholders' equity | 247,456,000 | 214,722,000 | 182,977,000 | |||||||
Invested Capital | 143,396,000 | 125,642,200 | 116,257,300 | |||||||
ROIC | 25.32% | 59.55% | 59.90% | |||||||
ROCE | 16.71% | 35.12% | 33.48% | |||||||
EV | ||||||||||
Common stock shares outstanding | 228,798 | 228,798 | 228,799 | |||||||
Price | 2,967.00 7.11% | 2,770.00 49.93% | 1,847.50 25.13% | |||||||
Market cap | 678,843,666 7.11% | 633,770,460 49.93% | 422,706,152 25.13% | |||||||
EV | 554,352,666 | 539,575,460 | 350,554,152 | |||||||
EBITDA | 52,871,000 | 87,690,000 | 77,308,000 | |||||||
EV/EBITDA | 10.49 | 6.15 | 4.53 | |||||||
Interest | 196,000 | 247,000 | 248,000 | |||||||
Interest/NOPBT | 0.44% | 0.31% | 0.36% |